Close Menu

PierianDx

The deal builds on a non-exclusive partnership signed in January 2019 and PierianDx will now support three more Illumina cancer sequencing assays.

PierianDx will integrate its cancer profiling assays with Pillar Biosciences' PiVAT bioinformatics pipeline on a GPDR-compliant platform.

The German hospital will build interpretation and reporting on the PierianDx Clinical Genomics Workspace for two Illumina assays.

The company offers products and services for analyzing, interpreting, and reporting clinical next-generation sequencing data with a focus on cancer.

Data from MMRF's Immune Atlas will be included in its recently launched CureCloud, a registry of clinical, genomic, and EHR data from multiple myeloma patients.

The company also said it has been awarded a research sequencing grant from Illumina Accelerator.

The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.

The companies will integrate PierianDx's informatics solution with two of Illumina's NGS cancer research panels and as well as future IVD products.

Allscripts subsidiary 2bPrecise will work with startup PierianDx to combine NGS and clinical data as they seek to advance precision care for cancer patients.

Malaysia-based ScienceVision has agreed to commercialize and distribute the PierianDx Clinical Genomics Workspace platform in Southeast Asian countries.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.